+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 19Years - 80Years
All Genders
ID07822087

Open-Label Phase 1 Study Evaluating Safety, Tolerability, and Dose Levels of ATORM-C in Crohns Disease Patients

Led by ORGANOIDSCIENCES LTD. · Updated on 2026-09-16

18

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ATORM-C, an investigational treatment made from autologous adult stem cell-derived intestinal organoids, in patients with Crohns disease. This Phase 1, open-label study aims to assess the safety, tolerability, and possible effects of ATORM-C on healing intestinal ulcers. The study involves a sequential dose-escalation design with three dose levels to determine the best dose for future research. Participants will receive a single dose of ATORM-C applied directly to a target intestinal ulcer during colonoscopy, with doses varying by the number of organoids per ulcer area. ATORM-C is administered with fibrin glue to help the treatment adhere locally to the ulcer. The trial evaluates three dose levels and monitors participants closely after this single administration. During the study, participants will undergo assessments including colonoscopy, laboratory tests, physical exams, vital signs, and electrocardiograms at specified intervals up to 24 weeks after treatment. Researchers will monitor safety by tracking dose-limiting toxicities and adverse events while exploring the treatments impact on ulcer size and healing using endoscopic scoring systems. The total participation period includes follow-up visits extending to 24 weeks post-treatment.

CONDITIONS

Brief Title

A Phase 1 Study of ATORM-C in Patients With Crohn's Disease

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here